Estimation of statistical cure from cancer using population-based data by Abreu, Sara Elisabete Ferreira de
Sara Elisabete Ferreira de Abreu
Estimation of Statistical Cure from
Cancer using Population-based Data
Sa
ra
 E
lis
ab
et
e 
Fe
rre
ira
 d
e 
Ab
re
u
outubro de 2015UM
in
ho
 |
 2
01
5
Es
tim
at
io
n 
of
 S
ta
tis
tic
al
 C
ur
e 
fr
om
 C
an
ce
r u
si
ng
 P
op
ul
at
io
n-
ba
se
d 
Da
ta
Universidade do Minho
Escola de Ciências

outubro de 2015
Dissertação de Mestrado
Mestrado em Estatística
Trabalho efectuado sob a orientação da
Professor Doutor Inês Sousa
e co-orientação do
Professor Doutor Luís Antunes
Sara Elisabete Ferreira de Abreu
Estimation of Statistical Cure from
Cancer using Population-based Data
Universidade do Minho
Escola de Ciências

“Success is stumbling from failure to failure with no loss of enthusiasm
”
Winston S. Churchill
ii
Acknowledgements
I would like to thank my supervisor prof. Inês Sousa for all help she has given me during
the study, I am also very grateful for cooperation with doc. Luís Antunes. A special
thanks for helpful advices and reading through my draft copies. I would also like to thank
the RORENO (North Region of Portugal Cancer Registry) for providing me the data for
my work. Additionally, I also highly appreciate the support I have received from my
family. The last but surely not least, I am also grateful to my boyfriend for helping me
and advising in the use of latex.
Sara Abreu
iii
Abstract
When studying cancer patient survival the interest lies in measure the time until the
occurrence of an event, as well as the study of factors associated with the occurrence
rates for that event. This is broadly known as survival data and the statistical method for
analyzing such data is usually referred to as "survival analysis". In this thesis, standard
survival methods, such as the Cox regression model, are recalled and a relative survival
approach is preferred over a cause-specific. The analysis is also extended to introduce
cure models as a useful tool to analyze and describe cancer survival data. Since some
patients actually achieve cure rather than prolong survival, the proportion of patients
cured of the disease can be a measure of interest and helpful in monitoring trends in
survival of curable disease. Cure models are not widely known and have never been used
in North Region of Portugal Cancer Registry (RORENO) reasearches. All these methods
are further applied on colorectal and melanoma skin cancer data from RORENO, where
this work were developed.
Relative survival estimates and the use of the Cox regression model indicate sex and age
as significant prognostic factors in both cancer types studied. With advantage in survival
for women and younger patients. Tumour thickness also appeared to be strongly related
to the prognosis for melanoma patients with bigger tumour sizes having worst survival
rates. Anatomical site where colorectal cancer had developed, colon or rectum, had a
different impact in the prognosis of the patient. When developed in the colon the survival
estimates were significantly higher. Cure percentages are consistent with survival
outcomes, since the identified factors with worse prognosis have also lower cure
proportions. According to sex, the proportion of cured patients present a decrease from
women (76% for melanoma, 60% for cancer of the colon and 53% for cancer of the
rectum) to men (65% for melanoma, 54% for cancer of the colon and 51% for cancer of
the rectum). Cure of melanoma and colorectal cancer patients is dependent on age and
sex, as well as anatomical site of the cancer cells (colon or rectum) for colorectal cancer
patiens.
Efforts in prevention methods are required in order to reduce the percentage of patients
presenting with bigger tumour sizes for melanoma. Besides the standard survival
analysis to identify prognostic factors and make an overview of the patients survival
during the follow-up, it is also important to know how many patients are actually being
cured and what factors may have influence on that. This is the only way to understand if
efforts and care methods adopted are being successful and actually enable cure from
cancer.
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Resumo
Na análise de sobrevivência de pacientes com cancro o interesse reside no tempo até a
ocorrência de morte, bem como o estudo de fatores com impacto nas taxas de ocorrência
para esse evento. Nesta tese, métodos usados na análise de sobrevivência, tais como
modelo de regressão de Cox, são recordados e uma abordagem de sobrevivência relativa
é preferível ao uso da sobrevivência observada. O estudo teve também como objectivo
introduzir os modelos de cura como uma ferramenta útil para analisar e descrever dados
de sobrevivência. Uma vez que alguns pacientes alcançam a cura para o cancro em vez
de prolongar a sua sobrevivência como paciente com a doença, a proporção de pacientes
curados do cancro pode ser uma medida útil e de interesse para compreender tendências
dentro dos pacientes que alcançam cura. Os modelos de cura nunca foram utilizados no
Registo Oncológico Regional do Norte (RORENO), sendo esta a primeira vez a serem
testados com dados de cancro colo-rectal e melanoma disponibilizados pelo RORENO.
Estimativas de sobrevivência relativa e modelo de regressão de Cox indicam o sexo e a
idade como fatores prognósticos significativos em ambos os tipos de cancro estudados,
com vantagem na sobrevivência para as mulheres e pacientes mais jovens. Verificou-se
também que pacientes com maiores tumores em termos de área e espessura aquando do
diagnóstico tendem a ter piores taxas de sobrevivência. O sítio anatómico onde o cancro
colo-rectal surgiu e se desenvolveu, cólon ou recto, tem impacto diferente no prognóstico
do paciente. Quando desenvolvido no cólon as estimativas de sobrevivência são
significativamente mais altas. As percentagens de cura são consistentes com os
resultados de sobrevivência, uma vez que os fatores identificados como tendo pior
prognóstico também tem as mais baixas proporções de cura. De acordo com o sexo, a
proporção de pacientes curados apresenta uma diminuição do sexo feminino (76 % para
melanoma, 60 % para o cancro do cólon e 53 % para o cancro do recto) para o masculino
(65 % para melanoma, 54% para o cancro do cólon e 51 % para o cancro do recto). Em
conclusão, a cura para o melanoma e cancro colo-rectal varia dependendo da idade e
sexo do paciente, assim como a localização anatómica das células cancerígenas (cólon
ou recto) tem impacto na probabilidade de cura para o cancro colo-retal.
Melhorias nos métodos de prevenção são necessárias a fim de reduzir a percentagem de
pacientes que apresentam tamanhos avançados dos tumores de melanoma no
diagnóstico. Para além de estudar a sobrevivência dos pacientes durante o período de
follow-up e os factores com influência no prognóstico, é também relevante conhecer a
percentagem de pacientes que alcançam a cura efectiva para o seu cancro e quais os
factores possivelmente associados. Só deste modo podemos compreender se os esforços
e métodos adoptados no tratamento estão a ser bem sucedidos e permitem alcançar a
cura para o cancro.
v
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Chapter 1
Introduction
Cancer is a class of diseases characterized for uncontrolled cell growth and tumor forma-
tion. There are over 100 types of cancers known with some being a lot more common
than others. Nowadays, this disease is affecting millions of people worldwide and it is the
main cause of death in economically developed countries. The incidence of cancer glob-
ally has increased and forecasts indicate significant increases in the future, due to growth
and ageing of the global population alongside with adoption of cancer-causing behaviors,
like smoking or poor diet [1]. This is a matter of huge concern and it is affecting our
society at economical level and in the way we live. Prevention is always better than cure
and considerable efforts were made over decades to comprehend the causes. Valuable
progresses were achieved in prevention programs, medical care and detection techniques.
Life quality, during and after treatment, as well as long survival times for cancer patients
have remarkably improved. And moreover, cure from cancer is increasingly becoming an
attainable goal, with a growing number of patients overcoming successfully the disease.
Researches and statistical analysis play an important role in comprehending cancer bur-
den, risk factors, survival and cure. Cancer epidemology is the science that studies causes
and trends of cancer diseases on populations rather than on separate individuals. Under-
standing how the disease evolves and what factors may have effect on that evolution and
origin is the key to develop treaments and find out ways of prevention. Monitoring health
care quality has become an integral part of Portuguese Oncology Institute (IPO) where
data are collected and analysed. This work aims to perform a biostatistical analysis us-
ing population-based data from RORENO (North Region of Portugal Cancer Registry) to
draw conclusions about time trends and prognostic factors associated to colonrectal and
melanoma skin cancer. Moreover, it also intends to apply a statistical modelling approach,
known as Cure Models, to estimate cure proportion.
1
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1.1 Cancer in Portugal and RORENO
Portugal is no exception regarding to what is happening with cancer worldwide. In 2007,
42374 new cancer cases were diagnosed with 13184 of them in the North Region. Which
represented a 7.7% gain in relation to 2006. The most common cancers are breast cancer
(incidence rate of 101.6/100000 ), prostate cancer (113.6/100000) and colorectal cancer
with (81.6/100000) [2].
The RORENO (North Region of Portugal Cancer Registry) was created in 1988 at the
Portuguese Oncology Institute (IPO) branch of OPorto. Since then, all cancer cases in the
north region have to be notified to registry. The geographic area covers OPorto, Braga,
Viana do Castelo, Vila Real and Bragança districts (representing about 30% of the total
Portuguese population), with is a mix of urban and rural inhabitants similar to Portugal
as a whole. Apart from collecting information on new cases as completed and updated
as possible, RORENO also analyze the data and manage studies and publications of great
value to clinicians, policymakers and researchers.
1.2 Objectives of the Thesis
This thesis focuses on the use of a new and complementary tool in biostatistics to measure
cure from cancer and identify factors that may have influence on that. Thus, the primary
aims of this thesis are:
1. Make a short overview on the survival analysis concepts.
2. Presentation of a mathematical method named Cure Models as a complementary
tool in survival analysis to estimate and model cure from cancer.
3. Applying Cure Models on melanoma and colonrectal cancer data from the North
Region of Portugal Cancer Registry to model the number of potentially cured pa-
tients.
4. Discuss on the gains of using Cure Models for drawing conclusions about cure.
All the survival analysis and Cure Models application was done in STATA software.
Chapter 2
Survival Analysis
All methodologies and studies presented in this thesis are in a survival analysis frame-
work. The purpose of this chapter is to present a brief introduction to survival analysis
and some important key issues in survival studies.
Survival analysis is a branch of statistics focused in the study of the time, T, until
an event occurs. In cancer patient survival analysis, event is defined as the death due
to cancer. Data are collected during a finite period of time and for some subjects the
event of interest (death) may not happen during the follow-up time. In these cases, data
is censored. The combination of censoring and differential follow-up makes a problem
impossible to solve with standard statistical methods.
To distinguish censoring times from times at which the event was observed for each
individual i, with observed time ti, is defined an event indicator, di, that takes the value 0
if the time was censored and 1 if the patient has experienced the event.
Time to event, T, is a positive random variable with distribution function F(t) and can
be described using the survival function S(t), the hazard function h(t) and the cumulative
hazard function H(t).
S(t) = P(T > t) = 1−F(t) (2.1)
S(t) is a non-increasing function over time and can only take values between 0 and 1.
Being 1 at time t=0 and 0 at time t=∞. The hazard function, h(t), is the instantaneous rate
at which events occur, given no previous events.
h(t) = lim
∆t→0
P(t ≤ T < t+∆t | T ≥ t)
∆t
(2.2)
The cumulative hazard describes the accumulated risk up to time t,
3
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H(t) =
∫ t
0
h(u)du (2.3)
The relationship among the functions described above can be expressed mathemati-
cally.
S(t) = exp(−H(t)) = exp(−
∫ t
0
h(u)du) (2.4)
h(t) =
d
dt
H(t) =
f (t)
S(t)
=− lnS(t)
dt
=−S
′(t)
S(t)
(2.5)
2.1 Concepts in Survival Analysis
2.1.1 Population-based Data
Data is the basis for any statistical analysis. Its quality and completeness are the key to
the relevance of the study, which in epidemiology research is even more valid.
In cancer patient survival studies, population-based cohort is often used rather than
individual cancer patient data because it lies more in the description of patient survival
in a demographically representative way [3]. Data collection in population-based studies
relies in the compilation of all new cancer cases occuring in a well defined population,
usually by the geographical region.
There are some advantages in using population-based data: (1) estimation of distri-
butions and prevalence rates of variables in the reference population can be obtained; (2)
risk factor distributions measured at baseline in a study with data periodic updates can
be compared with distributions in the future cross-sectional samples, so as to assess risk
factors trends over time; (3) a representative sample is the ideal way to carry out unbiased
evaluations of relations [4] [5].
In this thesis, it is of interest to use population-based cohort to analyze cancer patient
survival in a defined population, that is the north region of Portugal.
2.1.2 Relative Survival
Relative survival is the standard method for quantifying cancer patient survival in population-
based data. Relative survival, R(t), uses the all-cause deaths and compares the observed
survival, S(t), with that which would have been expected if the cancer patients have had
the same mortality rates as in the general population, S∗(t) .
R(t) =
S(t)
S∗(t)
(2.6)
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The expected survival (or background mortality rate) is obtained from national mortal-
ity statistics stratified by sex, age, calendar year and possibly other covariates. Although
this statistics include deaths due to cancer, the impact on the estimated background risks
of death can be negligible. There are several approaches to estimate the expected survival,
the most common are the Ederer I and II and the Hakulinen methods [6].
The reason for use relative survival rather than cancer-specific survival is that it does
not rely on the classification of cause of death, which is unlikely to be available or poorly
reported in population-based studies [7] [8].
On the hazard scale, we can write the overall hazard, h(t), as
h(t) = h∗(t)+λ (t) (2.7)
where h∗(t) is the expected hazard (mortality) rate and λ (t) the excess hazard (mor-
tality) rate.
The relative survival and the overall hazard can vary by covariates, z, such as sex,
age, stage or calendar year of diagnosis. The expected mortality vary by the stratification
factors given in the mortality rates, z′ , which are usually a subset of z.
R(t;z) =
S(t;z)
S∗(t;z′)
(2.8)
h(t;z) = h∗(t;z)+λ (t;z) (2.9)
2.1.3 Cox Proportional Hazards Model
The Cox Proportional Hazards Model is the most used model for analysis time to event
data on medicine [9]. It explores the relationship between the survival of a patient
and several explanatory variables. Cox’s method is not a fully parametric model since
it doesn’t assume any particular distribution for the survival times, instead it assumes that
the effects of the different variables on survival are constant over time and are additive in
a particular scale [10] . The hazard function for a patient indexed with i can be written as
h(t;zi) = h0(t)eziβ (2.10)
where β is the vector of regression coefficients and h0(t) is the so-called baseline
hazard function. Since the h0(t) is only time dependent, the hazard ratio between two
different observations does not depend on time
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h(t;zi)
h(t;zj)
=
h0(t)eziβ
h0(t)ez jβ
(2.11)
To estimate the β coefficients a partial likelihood function is maximized
logL(β ) = ∑
i, j=1,...,n
{
ziβ − log
 ∑
j=t(j)≥t(i)
ezjβ
]}
(2.12)
2.1.4 Survival Analysis Limitations
Since survival time is a difference between the date of death and the time of clinical di-
agnosis, it is sensitive in changes in either of the dates. Increasings in the 5-year relative
survival rate can be affected by lead-time bias and be easily misleading. For instance, if
new procedures enable ealier diagnosis without increase the potential of cure and post-
pone death, the date of death is the same as in the late diagnosis but the survival time is
bigger. This leads to increases in survival rates, but actually this situation does not rep-
resent effective improvements in survival for cancer patients. Five-year relative survival
rate is extremely useful when comparing cancer therapies in a randomized trial but its use
is inadvisable in comparisons across time (or place) [11] . Cox regression model is only
appropriate when the interest relies in the relative effect of a covariate on the hazard rate
[12] . So, classical survival analysis methods do not provide direct estimates of the cure
fraction, and thus do not elucidate if the survival improvement over time occurs due to
actual cure or prolongation in survival time.
In order to evaluate progress against cancer, one must simultaneously interpret trends
in incidence, mortality, survival and cure proportion.
Chapter 3
Cure Models
For many types of cancer, the mortality among patients has seen to return to the same level
as in the general population with patients no longer experiencing additional or excess
mortality compared with the population from which they are drawn. This is assumed
to be a definition of cure at a population level, called population or statistical cure, and
differs conceptually from “medical cure” for individual patients [13]. In this situation, we
observe that R(t) reaches a plateau. For example, in Figure 3.1 relative survival reaches
0.4 and does not go below this.
Figure 3.1: Plateau for Relative Survival
Classical survival analysis focuses in the study of time to the event (death) and assume
7
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that every individual is susceptible to the event. Sometimes, however, the data come
from a population where a proportion of individuals do not die from the disease and are
actually cured. For such cases, reporting the time to event/survival does not bring enough
information on the actual condition of the patient and does not take into account the
possibility of cure.
Cure models, on the other hand, assume the population of patients divided into two
distinct groups: one being cured with respect to the disease and the other one experiencing
the event (death from cancer), with separate survival distributions for each. Estimates
of the cure fraction can be obtained, which are easier to interpret and more relevant to
patients and clinicians than the measures reported from traditional approaches [14]. For
the uncured group of individuals measures of the survival time can be provided and, unlike
the standard survival methods, are not overestimated because they do not take into account
patients who are cured.
Since cure models give information on the cure fraction and survival times of uncured,
they elucidate if the survival improvement over time occurs due to effective cure or pro-
longation in survival time [15], [16]. Another advantage is that they can also provide
possibilities for studying temporal trends when analyzing the four possible scenarios.
Figure 3.2: Hypothetical changes in the cure fraction and median survival of the uncured
between 2 periods of diagnosis
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Figure 3.2 shows the different scenarios: (a) represents a general improvement, treat-
ments are able to cure more individuals and provide a longer survival time for those un-
cured; (b) might happen when more patients are cured and those who did not achieve
cure have the worst prognosis. So, the survival of the uncured decrease, while the cure
proportion increase; (c) occurs when treatments and procedures only enable to prolong
life for cancer patients instead of effective cure. Or, (c) could also occur if we have ear-
lier diagnosis without affecting the time of death. That is, lead time bias and is often
suggested as an explanation for improvements in patient survival when using traditional
survival methods. An advantage in a cure model framework is that we have information
on cure fraction which cannot be affected by lead time bias, and can therefore be used
when lead time is a concern; (d) might occur if new procedures able earlier diagnosis
leading to greater possibilities for cure. Patients in this case belong to the cure group,
thus the cure fraction increase. Still, the survival of the uncured group does not change.
There are, of course, other explanations for these four scenarios and they should be
interpreted according to the situation and knowledge of clinical practice.
3.1 Mixture Cure Model
As the name suggests, this model assumes patients as a mixture of two types: ones who
experience the event of interest (death from cancer) and the other ones who are cured
from the disease, and thus have the same mortality rate as the expected in the general
population [17] [18] [19]. The model can be written as
S(t) = pi+(1−pi)Su(t) (3.1)
where pi is the proportion cured and Su(t) is the survival function of the uncured
individuals, for which the parametric Weibull or (more rarely) Lognormal distribution is
used. Extending the model to incorporate background mortality, we have
S(t) = S∗(t)(pi+(1−pi)Su(t)) (3.2)
Which can be expressed on a hazard scale as
h(t) = h∗(t)+
(1−pi) fu(t)
pi+(1−pi)Su(t) (3.3)
where fu(t) is the probability density function associated with Su(t).
When introducing covariates, z
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S(t;z) = S∗(t;z′)(pi(z)+(1−pi(z))Su(t;z)) (3.4)
Link functions can be used to model the dependence between the covariates and the
cure proportion, pi;
1. The identity link, pi = zβ . Covariate effects are in units of the cure proportion.
2. The logistic link, log( pi1−pi ) = zβ . Covariate effects are expressed as log odds of
cure.
3. The log(−log) link, log(−log(pii)) = zβ . Covariate effects are expressed as (log)
excess hazard ratios.
where β is a vector of parameters to be estimated for covariates.
This model allows covariates to be different for cured patients and patients who are
not cured. For example, the survival distribution of uncured can depend on only a subset
of covariates included to model the cure proportion, or the survival distribution of the
uncured can be assumed to not vary by covariates at all.
For survival models, the general log-likelihood can be defined as
log L=
N
∑
i=1
dilog h(ti)+ log S(ti) (3.5)
Where N is the number of individuals and di the event indicator, as previously defined.
Estimation is performed by maximum likelihood. The general log-likelihood for the
mixture cure model incorporating covariates is
logL=
N
∑
i=1
dilog
(
h∗(ti;z′i)
(1−pi(zi))+ fu(ti;zi)
pi(zi)+(1−pi(zi))Su(ti;zi)
)
+log(pi(zi)+(1−pi(zi))Su(ti;zi))
(3.6)
3.2 Non-mixture Cure Model
The Non-mixture model was first introduced to model tumor recurrence, where the cure
fraction is the probability that no cancer cells with potential of metastasizing remains
[13]. Moreover, this model can also be applied to estimate the cure fraction since it
provides an asymptote for the survival function at the cure proportion.
The overall survival function can be written as
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S(t) = piFy(t) (3.7)
When incorporating background mortality, all-cause survival can be expressed as the
product of the expected survival and the disease-related (relative) survival
S(t) = S∗(t)piFy(t) (3.8)
where Fy(t) is a distribution function with Sy(t) its corresponding survival function,
and as for the mixture model, a Weibull distribution is often used.
Thus, the overall hazard can be expressed as
h(t) = h∗(t)− log(pi) fy(t) (3.9)
With fy(t) being the probability density function for Fy(t). Including covariates, z, to
model the cure proportion
S(t;z) = S∗(t;z′)exp(log pi(z)(1−Sy(t;z))) (3.10)
The non-mixture model can be rewritten as a mixture cure model
S(t;z) = S∗(t;z′)
[
pi(z)+(1−pi(z))(pi
Fy(t;z)−pi(z)
1−pi(z) )
]
(3.11)
The same link functions described for the mixture model can also be used here for
modelling of the cure proportion.
The log-likelihood function in this case is
log L=
N
∑
i=1
dilog
(
h∗(ti;z′i)− log pi(zi) fy(ti;zi)
)
+ log
(
pi(zi)− log pi(zi)Sy(ti;zi)
)
(3.12)
3.3 Flexible Parametric Cure Model
The models described above assume a Weibull or a Lognormal distribution for the survival
function, but these parametric distributions are often inappropriate because of the lack of
flexibility to capture the shape of some hazard functions [20], [21]. So, the idea behind
the Flexible Parametric Cure Model is to use restricted cubic splines to approximate the
shape of the underlying hazard function [22], [23].
Cure Models 12
Starting from a Weibull survival function, S(t)
S(t) = exp(−λ tγ) (3.13)
If we transform to the log cumulative hazard scale, we get
logH(t) = log(−logS(t)) = logλ + γlogt (3.14)
Which is a linear function of logt. Now, rather than assuming linearity with logt
restricted cubic splines are used to model the log cumulative hazard function.
logH(t) = γ00 + γ01υ1(x)+ ...+ γ0K−1υK−1(x) = s(x;γ0) (3.15)
Where x= logt, K is the number of knots and the jth basis function is defined as
υ j(x) =
{
x, f or j = 1
(x− k j)3+−λ j(x− k1)3+− (1−λ j)(x− kK)3+ f or j = 2, ...,K−1
(3.16)
In which u+ = u if u> 0 and u+ = 0 if u≤ 0, k1 is the position of the first knot, kK the
position of the last knot, k j the position of the jth knot and λ j = (kK−k j)/(kK−k1). The
splines used are restricted cubic splines, which has the restriction that the fitted function is
forced to be linear before the first knot and after the final knot. The shape of the restricted
cubic splines functions is dictated by the available data, so the number and location of
knots used has to capture the underlying shape and recent analysis suggest 4-6 knots as
being sufficient. With no knots, the spline reduces to a linear function, and these models
are equivalent to Weibull, log-logistic and lognormal models.
Introducing covariates, z,
logH(t;z) = s(x;γ0)+βz (3.17)
It is of interest to extend this general model idea to a relative survival framework. By
integrating equation (2.7), the overall cumulative hazard, H(t), becomes
H(t) = H∗(t)+Λ(t) (3.18)
Where H∗(t) is the cumulative expect hazard andΛ(t) is the cumulative excess hazard.
The log cumulative excess hazard scale is then modelled using restricted cubic splines to
estimate the baseline hazard in the same manner as described above.
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log(−logR(t;z)) = logΛ(t;z) = logΛ0(t)+βz= s(x;γ0)+βz (3.19)
In which Λ0(t) is the cumulative baseline function and covariates having an additive
effect.
The reasons for modelling on the log cumulative hazard scale instead of the log hazard
scale are: the log cumulative hazard is a relatively stable function with easier capture of
its shape; it is also easier to transform to the survival and hazard functions without the
need for numerical integrations and under the proportional hazards assumptions covariate
effects are interpreted as hazard ratios [20].
When cure is reached the excess hazard rate is zero and the cumulative excess hazard
will be, therefore, constant after this point in time. Cure proportion estimation, in a
flexible parametric model, is done by forcing the log cumulative excess hazard to not
only be linear but also to have zero slope after the last knot. All spline functions are
zero before the first knot except the linear, υ1(x) = x, and imposing constraints on the
parameter, γ01, it is possible to determine the slope of the spline before the first knot. But
this is supposed to happen after the last knot, and the only way to get it is by treating
the knots in reversed order, “backwards”, so that all splines variables except the linear
take the value zero after the last knot. Restriction on the parameter for the linear spline
variable (γ01 = 0) impose a cure point and enable estimation of the cure proportion. The
spline basis, υ j(x), are then defined
υ j(x)=
{
x, f or j = 1
(kK− j+1− x)3+−λ j(kK− x)3+− (1−λ j)(k1− x)3+, f or j = 2, ...,K−1
(3.20)
The relative survival function for the flexible parametric cure model becomes
R(t) = exp
(
− exp(γ00 +0×υ1(x)+ ...+ γ0K−1υK−1(x))
)
(3.21)
It can be seen that the flexible parametric cure model is a special case of a non-mixture
cure model with pi = exp(−exp(γ00)), and Fy(t) = exp(γ02υ2(x)+ ...+ γ0K−1υK−1(x)).
Fy(t) is a distribution function as long as the excess mortality is not negative, which is
very uncommon. As for the non-mixture and mixture model, the flexible parametric cure
model can be written as a proportional hazards model, as long as no time-dependent
effects are modelled.
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When incorporating covariates and interactions between covariates and splines for
time,
R(t) = exp
(
− exp(γ00 +βz)
)
exp
(
γ02υ2(x)+ ...+ γ0K−1υK−1(x)+
D
∑
i=1
s(x;γi)zi
)
(3.22)
Where D is the number of time-dependent covariate effects and s(x;γi) is the spline
function for the ith time-dependent effect. The constant parameters, γ00 and β , are used
to model the cure proportion and the time-dependent parameters are used to model the
distribution function of Fy(t). The constraint of a zero effect for the linear spline term
has to be incorporated for each modeled spline function. Since all splines variables take
the value zero after the last knot, the constant parameter, γ00, in equation (3.22) , is the
log cumulative excess hazard at and beyond the last knot for the reference group, and can
therefore be used to predict cure.
All parameters are estimated by maximum likelihood. Cure proportion and the sur-
vival of uncured can be predicted in the same way as for the non-mixture model, and the
median survival time of uncured, or any other percentile, is predicted using the Newton-
Raphson algorithm [24] .
As for the mixture and non-mixture models, the flexible parametric cure model can
be written as a non-proportional hazards model, as long as time-dependent effects are
modelled. In cancer patient survival studies it is very common to have time-dependent
effects with interactions between covariates and splines for time.
Chapter 4
Case Study Melanoma
Melanoma is a type of skin cancer that develops in the pigment cells present in the skin.
It has the ability, in later stages, to spread (or metastasize) to other parts of the body
and cause serious illness and death. There has been a worldwide increase in incidence of
melanoma among all caucasian populations over the last decades [25]. A recent study per-
formed with data from European cancer registries shows that the highest rates were seen
for the Scandinavian and north-western European countries, while Portugal and Spain had
the lowest incidence rates [26] . Much of the increase in melanoma occurence has been
suggested to be caused by the rise in excessive exposure to sunlight alongside with skin
type. That explains why Caucasian individuals and people who are susceptible to red sun-
burn have the highest risk of developing the disease over Africa, Asia and Middle-East
individuals. Despite increasing trends in melanoma incidence, the prognosis for those
affected has improved. This is most likely due to earlier detection and new adopted treat-
ment care techniques. In fact, many studies report that prognosis is mainly influenced by
tumour thickness and ulceration [27] and this leads to the high importance of effective
early detection. But other factors such sex, age at diagnosis and anatomical site are also
known to affect patients survival [28].
4.1 Data
The study population were all patients with a diagnosis of skin melanoma cancer in the
north region of Portugal between 1998 and 2003 with follow-up to the end of 2013. Pa-
tients that have been also diagnosed with other cancers, as well as patients with unknown
status were excluded, making up a total of 760 eligible individuals for the analysis. The
original RORENO registrations has information on a lot of variables, however records
from 1998-2003 are extremely incomplete. For that reason the variables considered in
15
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the study had to be the ones suggested in latter studies with the most completeness in the
available data:
• Sex
Identifies the patient gender: 1-Male, 2-Female;
• Age Group
The variable age at diagnosis is recoded into categories commonly used (15-44,
45-54, 55-64, 65-74, 75+);
• Typology
Specifies the zone type in which patients live, according to the official classification
from INE (Portuguese Institute of Statistics): 1-APR, 2-AMU, 3-APU. A region is
classified as predominantly rural area (APR) if does not belong to a locality with
a population of 2 000 or more inhabitants, or if has a population density equal or
below 100 inhabitants per km2. Averagely urban (AMU) is an area that complies,
at least, one of the following requirements: (1) the greater value of the average be-
tween the weight of population and of area in the parish’s total is urban space, with
the weight of the area in predominantly rural space surpassing 50% of the parish’s
total area; (2) the greater value of the average between the weight of population and
of area in the parish’s total is semi-urban space, with the weight of the area in pre-
dominantly rural space not surpassing 50% of the parish’s total area; (3) the parish
is the location of the municipal hall and has a population equal or below 5 000 in-
habitants; (4) the parish contains totally or partially a locality with a population of
2 000 or more inhabitants and less than 5 000 inhabitants, with the weight of the
population in the parish’s total population or in the locality’s total population be-
ing equal or higher than 50%. Lastly, a region is labeled predominantly urban area
(APU) when follow one of these requirements: (1) the greater value of the average
between the weight of population and of area in the parish’s total is urban space,
with the weight of the area in predominantly rural space not surpassing 50% of the
parish’s total area; (2) the parish is the is the location of the municipal hall and
has a population of more than 5 000 inhabitants; (3) the parish contains totally or
partially a locality with a population of 5 000 or more inhabitants, with the weight
of the population in the parish’s total population or in the locality’s total population
being equal or higher than 50% [29] .
4.1 Data 17
• T
This variable measures the tumour size/thickness into two new categories formed
by grouping: T1-T2, T3-T4;
• Anatomical Site
Region of the human body where the tumour is located. Its recoded into four cate-
gories: Head/Neck, Trunk, Upper Extremity and Lower Extremity.
Table 4.1: Cohort characteristics
Frequency (%) Number of deaths Percentage dying
during follow-up during follow-up
Sex
Male 285 (37.50%) 155 54.39
Female 475 (62.50%) 199 41.89
Age Group
15-44 199 (26.18%) 44 22.11
45-54 133 (17.50%) 40 30.08
55-64 140 (18.42%) 52 37.14
65-74 153 (20.13%) 103 67.32
75+ 135 (17.76%) 115 85.19
Typology
Rural 48 (6.32%) 33 68.75
Averagely Urban 102 (13.42%) 49 48.04
Urban 607 (79.87%) 270 44.48
Unknown 3 (0.39%) 2 66.67
T
T1-T2 395 (51.97%) 165 41.77
T3-T4 109 (14.34%) 75 68.81
Unknown 256 (33.68%) 114 44.53
Anatomical Site
Head/Neck 144 (18.95%) 80 55.56
Trunk 180 (23.68%) 82 45.56
Upper Extremity 72 (9.47%) 28 38.89
Lower Extremity 216 (28.42%) 100 46.30
Unknown 148 (19.47%) 64 43.24
Total 760 (100%) 354 46.58
Table 4.1 presents simple statistics of the variables. There is not a similar propor-
tion of males and females in the cohort. More women were diagnosed with the disease
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comparing to men, comprising 63% of the total cohort. The most common age group at
diagnosis was 15-44 years, for the other age groups the number of patients was very sim-
ilar, around 140 diagnosis between 1998-2003. The percentage dying during follow-up
increased from the newest to the oldest group, suggesting age as a risk factor in prognosis.
The number of patients who lived in a urban area is enormous, representing 80% of the
study population. The other ones are from a moderately urban area and only 6% resided
in the countryside. It should be noted that in the region where study population are draw
68% of the people reside in urban areas, while 21% and 11% are from moderately urban
and rural areas, respectively.
The variable T is unknown for 34%, because this information wasn’t necessarily re-
quired in the registries in 1998-2003. Among ones with information on this parameter,
there were a lot more beeing diagnosed with a smaller size of the tumour. The num-
ber of deaths during follow-up was higher in the group of patients with tumour sizes in
the biggest category. The regions of the body were tumours started to appear were di-
verse. Melanoma on the lower extremity was the most common, followed by trunk and
head/neck, while cases on the upper extremity were just a few (9%).
4.2 Survival Estimates
The purpose of this section is to present an overview of the survival for the set of patients.
The survival rates were calculated for each variable in order to compare the influence
of the diferent groups in the survival. The relative survival method for cancer survival
estimation was Ederer II [30] .
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4.2.1 Sex
Figure 4.1: Relative Survival by Sex
Table 4.2: Survival by Sex
Years after Diagnosis
1 5 10 Log-Rank Test
Observed Survival
Male 76.5% 60.0% 51.2% p-value<0.001
Female 87.1% 71.1% 63.9%
Relative Survival
Male 80.6% 70.2% 66.3%
Female 90.2% 79.0% 76.4%
Figure 4.1 suggests a clear difference in survival among genders. Women with melanoma
appear to have better prognosis than men. In Table 4.2, 5-year relative survival is 79% for
females and decreases for 70 % in males, while after 10 years of follow-up the survival
rate becomes 76% for women and 68% for men. From the first year after diagnosis to the
tenth there was a relative survival declined of about 14%for both sexes.
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4.2.2 Age Group
Figure 4.2: Relative Survival by Age Group
Table 4.3: Survival by Age Group
Years after Diagnosis
1 5 10 Log-Rank Test
Observed Survival
15-44 93.5% 86.4% 80.9% p-value<0.001
45-54 96.2% 79.0% 72.9%
55-64 91.4% 72.9% 65.7%
65-74 90.9% 62.8% 45.1%
75+ 76.9% 43.3% 22.4%
Relative Survival
15-44 93.6% 87.1% 82.2%
45-54 96.6% 80.5% 76.2%
55-64 92.2% 76.3% 73.4%
65-74 92.8% 70.9% 61.2%
75+ 83.6% 68.9% 66.8%
Looking at Table 4.3 is easy to see that in the first years after diagnosis survival estimates
are more similar to each other and tend to differ over time. During the all follow-up period
there is indication of different patterns in survival and the prognosis seems to get worse
from the 15-44 to 75+ age group. The relative survival curve of the 75+ age group rises
a little bit after 7 year following diagnosis. This is medically impracticable and it may
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be due to the use of a inappropriate life table, deficient follow-up (it may be possible that
not all deaths were reported) or can also be the case that these patients received better
treatments that improved their survival.
4.2.3 Typology
Figure 4.3: Relative Survival by Typology
Table 4.4: Survival by Typology
Years after Diagnosis
1 5 10 Log-Rank Test
Observed Survival
Rural 79.2% 56.3% 37.5% p-value=0.001
Averagely Urban 90.2% 70.6% 58.8%
Urban 90.9% 71.5% 61.1%
Relative Survival
Rural 82.3% 67.5% 52.7%
Averagely Urban 92.1% 78.6% 73.2%
Urban 92.7% 78.6% 74.2%
Both Figure 4.3 and Table 4.4 shows that survival is very similar among melanoma
patients from urban and averagely urban areas, while the patients that live in rural regions
have shown lower levels in survival, specially beyond six years after diagnosis.
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4.2.4 T
Figure 4.4: Relative Survival by T
Table 4.5: Survival by T
Years after Diagnosis
1 5 10 Log-Rank Test
Observed Survival
T1-T2 94.9% 77.2% 65.1% p-value<0.001
T3-T4 84.4% 51.4% 37.6%
Relative Survival
T1-T2 96.9% 85.2% 79.8%
T3-T4 86.6% 57.5% 46.1%
Patients diagnosed with smaller tumours size/thickness showed better chances to resist
the disease. Table 4.5 present a survival rate of about 85% in the end of the fifth year.
Whereas, the ones with tumours categorized as T3-T4 revealed more difficulty struggling
the disease with a survival estimate of 46% in the end of the 10 years of follow-up period.
4.2 Survival Estimates 23
4.2.5 Anatomical Site
Figure 4.5: Relative Survival by Anatomical Site
Table 4.6: Survival by Anatomical Site
Years after Diagnosis
1 5 10 Log-Rank Test
Observed Survival
Head/Neck 91.7% 68.1% 53.5% p-value=0.1364
Trunk 91.1% 70.6% 58.3%
Upper Extremity 94.4% 77.8% 63.9%
Lower Extremity 89.8% 69.8% 60.5%
Relative Survival
Head/Neck 95.6% 81.4% 80.3%
Trunk 92.3% 75.2% 67.0%
Upper Extremity 95.4% 82.4% 72.3%
Lower Extremity 91.4% 76.1% 71.4%
Relative survival curves in Figure 4.5 and estimates from Table 4.6 indicate that there
is no big difference between the prognosis of patients diagnosed with tumours in distint
anatomical sites, since the results of the survival estimates do not vary that much.
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4.3 Cox regression model for survival
The aim of this section is to apply a Cox regression model for the achievement of factors
with influence on the survival time of a patient. A Cox model was built under backward
selection method, including at each step the variable with the largest increase in the χ2
model or equivalently the largest reduction in the log-likelihood. No relevant interactions
between the considered variables were identified. As a result, the final model is shown in
the next table with estimated hazard ratios associated with the set of covariates, as well as
their 95% confidence intervals and corresponding p-values.
Table 4.7: Cox model fitted to available data from Melanoma skin cancer patients
Years after Diagnosis
Prognostic Factor Category Hazard Ratio 95% CI p-value
Sex Male 1
Female 0.70 ]0.54,0.91[ 0.007
Age Group <65 1
65-74 2.83 ]2.06,3.87[ <0.001
75+ 4.94 ]3.59,6.80[ <0.001
Typology Rural 1
Averagely Urban/Urban 0.63 ]0.41,0.98[ 0.041
T T1-T2 1
T3-T4 2.18 ]1.65,2.88[ <0.001
Figure 4.6: Cox-Snell Residual
To evaluate the fit of the model Cox-Snell residuals were plotted. Figure 4.6 mostly
confirm the adequacy of the Cox model to fit the data.
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The predictor anatomical site is not in the final model, with summary results presented
in Table 4.7, because it was clearly not statistically significant, p-value=0.88. Consid-
ering age group as a prognostic factor, there was no statistical difference among patients
bellow 65 years old. However, from looking at the hazard ratios the model indicates that
as a patient change from an age lower than 65 to the age group between 65 to 74 years
old (assuming all other variables helding constant) the risk of death increases in 183%.
If the age agroup was altered to less than 65 to more than 75 years old, the rate of death
increases by 394%. When going from a male to female patient the risk of death decreases
in 30%. Patients diagnosed with tumor thickness evaluated as T3-T4 have 118% more
risk of dying, comparing with ones diagnosed with T1-T2 and considering all other vari-
ables constant. Altough there is no significant statistic difference in prognosis for patients
from urban and averagely urban areas, when comparing to rural areas patients there is
significance of a decrease in 37% the risk of death.
4.4 Estimating and Modeling cure with Cure Models
In this section the cure models presented in Chapter 3 were applied to the data to demon-
strate its applicability and potential to study temporal trends of the cure proportion.
The mixture and non-mixture cure models did not converge, probably because of its
known weakness when relative survival is high or inappropriate distributions to describe
the survival of the uncured patients. A flexible parametric cure model approach was
considered with backward elimination method, starting with all variables as well as in-
teractions between them and using likelihood-ratio tests to test which models fitted the
data best. To evaluate how sensitive were the results to different numbers or locations
of knots, the most statistically significant model was fitted with different numbers and
places of knots. Results confirmed that the models are generally insensitive to that as
long as knots are placed over the whole follow-up period and the last knot is positioned at
the last observed death time. The final model only includes age group and sex. Estimated
relative survival curves of the flexible parametric cure models, stratified by each variable
were plotted in Figures 4.7 and 4.8 against life table estimates of relative survival, with
95% confidence intervals, obtained using Ederer II method.
Figure 4.8 shows the flexible parametric fit of observed data by age group and it is
obvious that patients above 65 years old fail the assumption of statistical cure needed for
cure models application, since its survival curve did not reach a plateau.
For both sexes, age groups 45-54 and 55-64 the flexible parametric cure model give a
good fit of observed data, indicating evidence of statistical cure since the survival curves
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level off within 10 years of follow-up. For the age group bellow 45 years old the model
failed to converge, because the survival was high (above 80%). For patients above age of
65 the graphs confirm that the assumption of cure is not reasonable and, therefore, cure
models should not be fitted and interpreted. The next reported results and considearations
only take into account the ages proved to be under the cure assumption.
Figure 4.7: Predicted Survival from the Flexible parametric cure model, compared to life
table estimates of relative survival for both genders
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Figure 4.8: Predicted Survival from the Flexible parametric cure model, compared to life
table estimates of relative survival for age groups
Table 4.8: Estimated proportion cured (%) and 95% confidence intervals by sex and age
group
Age 45-54 Age 55-64 All 45-64
Men 69.07 ]51.59 , 81.32[ 63.19 ]48.36 , 74.83[ 64.83 ]54.14 , 73.63[
Women 79.54 ]68.37 , 87.13[ 71.26 ]58.04 , 80.98 [ 75.62 ]67.33 , 82.09[
All 75.84 ]66.66 , 82.82[ 66.70 ]58.13 , 73.90[
Table 4.8 shows that cure fraction is lower as we go from the newest age group to
the oldest for both men and women. Results also vary according to gender, with women
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achieving better estimates ranging from 80% in ages between 45 and 54 to 71% in the
following ages up to 64. Men’s cure percentages do not reach 70%, being 69% among
younger patients in the study and 63% for the others. However the uncertainty regarding
this estimate is higher, since the confidence interval magnitude for the age group 45-54
lies between 52% and 81%. For the older patients the confidence interval is also wide
with the lower limit being below 50%.
Figure 4.9: Predicted Survival of Uncured for Men
Figure 4.10: Predicted Survival of Uncured for Women
The survival of the uncured in men plotted in Figure 4.9 seem to have a more notable
decrease within the 5 years of follow-up. While the group of uncured women, represented
in Figure 4.10, appears to resist better the disease.
4.5 Discussion
In this chapter, an exploratory survival analysis was performed to illustrate relative sur-
vival behaviour during the 10 years follow-up for melanoma patients from North Region
of Portugal Cancer Registry. The aim was to understand how patient features influence
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and vary the survival over time. Relative survival curves by gender in Figure 4.1 and
estimates in Table 4.2 corroborate what many studies report, that women have a better
prognosis. Men have relative survival results below 10% of the ones estimated for women
during the whole period. In the first year after being diagnose with melanoma, the rel-
ative survival was quite high (81% for men and 90% for women). Then, after 5 years
the survival declined 11% for both and from the fifth to the tenth year the survival curve
began to plateau. These results support the evidence of long-term survival in melanoma
skin cancer. The prognostic potential of age is also not surprising. It was confirmed that
survival reduces with advanced age at diagosis and is most pronounced among patients
on the age of 75 or above [31] . About the evaluation on survival according to the zone
type in which patients live, we can say that there is no difference among ones from av-
eragely urban and urban areas. However, people who live in rural regions had worse
survival estimates. Nevertheless, it is important to notice that there are only about 6%
of patients from rural areas in the entire cohort which may not be enough reliable. Our
findings on tumor thickness influence on survival testify it as an important prognostic pre-
dictor. Patients diagnosed with a tumour size/thickness classified as in the most advanced
stage had higher mortality. Therefore, early detection remain of high importance in the
treatment/long-term survival success. In Section 4.3 a Cox regression model was built up
to identify the potential risk factors associated with survival probability. This analysis get
us closer to the prognostic profile of a specific patient and may help the clinician both in
the communication of risk and in the follow-up strategy. The final model include sex, age
group, typology and tumour size/thickness as significant prognostic factors. Age group is
the most important prognostic factor as well as size. In fact, patients above 65 years old
at diagnosis showed a risk of dying by the disease much bigger than younger ones. And
the risk is even worse if we consider patients with 75 or older. The model corroborate
what relative survival estimates suggest for tumour size/thickness influence. Actually, be-
ing diagnosed with tumour size/thickness in the most advanced stage is twice as likely
to compromise the death risk. This information is of great value giving insights in how
crucial early detection is. That is why it is so important to raise awareness, strengthening
or developing clinical methods and techniques in order to boost vigilance and potential
to a detection as early as possible. There is also statistical significance regarding gender
distinction in survival trends with a better prognostic for women. Among patients from
urban and averagely urban areas there is no significant differences in survival behaviour,
but when comparing to patients who come from rural regions the survival trends were
not similar. These patients showed higher mortality and a worse prognostic. However, it
should be noted that there are only about 6% of patients from rural areas in the entirity
cohort which may not be enough representative or may be confounded with differences
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in other factors like sex, tumour thickness, anatomical site and so on.
Cure models can be more appropriate and a useful alternative to the standard Cox
proportional-hazards regression model when presence of long-term survivors is clear.
Since we have a population with long-term survival that verifies the assumption of cure,
the interest now lies in knowing the proportion of patients cured of their disease and what
happen to those that are not cured. Therefore, additional information can be gained from
using a cure model analysis beyond a standard Cox analysis. Measure the cure fraction
can be more relevant, easier to interpret and also provide greater possibilities for studying
temporal trends. In this study, we were able to estimate the cure percentages by age group
and gender. The other covariates available in the data, typology, tumour size/thickness
and anatomical site did not fit the observed data to reach a plateau within the follow-up
period. Cure proportion estimates are consistent with the findings obtained by cox regres-
sion model and relative survival estimates with women and younger age groups having
better cure percentages. Younger patients are likely to tolerate treatments better than
older ones, and therefore more likely to achieve cure. In the group of uncured patients,
men mortality has higher rates with a five year relative survival of about 10%. While
women seem to resist for a longer period of time, reaching a survival below 10% only af-
ter 9 years of follow-up. Greater cure rates in women indicate biological differences and
responses to disease and treatment between genders. Nevertheless, another factors may
also have impact like earlier detection or younger ages at diagnosis for women, or even
social and psychological features with distinct influence in prognosis for both genders.
Chapter 5
Case Study Colorectal Cancer
Colorectal cancer is the term for the malignant tumours that develop in the large intes-
tine, either the colon or the rectum. These two types of cancer are usually referred as
the same, since they presence various features in common and can only differ in terms of
treatment procedures. Also known as bowel cancer, this kind of disease has been reported
as the second most common cancer in Europe [32] . However, it has been proven not
to be uniformly incident throughout the world. Many studies report increases in the inci-
dence among economically transitioning countries, whereas rates stabilized or decreased
in long-standing economically developed countries. This reflects the adopting results of
western lifestyles and behaviors, like poor diets, physical inactivity and smoking. Mortal-
ity rates are also higher in low-resource countries and continue to rise, while in economi-
cally developed countries they have declined [33] . This is a matter of huge concern and
had led to efforts in developing medical treatment and techniqes that improved the sur-
vival and long-term outcome of colorectal patients. Once the cure percentage and median
survival among patients is increasing, the factors that may have an influence in the prog-
nosis were also tempted to understand. Age and stage at diagnosis seem to be the main
important prognostic factors for this cancer patients [34] . In Portugal, colorectal cancer
is the second most common cancer afecting both men and women. In 2008 the incidence
rate of colorectal cancer cases among men was (146,4/100.000) and (90,2/100.000) for
women [35] .
5.1 Data
The data used for this study consisted in all adults from both sexes above 15 years-old
diagnosed with malignant colorectal cancer between 1998 and 2003 in the north region of
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Portugal. Information on the patient records was obtained from RORENO registrations
comprising a total of 4489 eligible records for the analysis.
• Sex
Identifies the patient gender: 1-Male, 2-Female;
• Age Group
The variable age at diagnosis is recoded into categories commonly used (15-44,
45-54, 55-64, 65-74, 75+);
• Typology
Specifies the zone type in which patients live. Coded in the same way as in melanoma
case study.
• Topography
Indicates in which part of the large instestine the cancer developed: 1-Colon, 2-
Rectum.
Table 5.1: Cohort characteristics
Frequency (%) Number of deaths Percentage dying
during follow-up during follow-up
Sex
Male 2493 (55.54%) 1674 67.15
Female 1996 (44.46%) 1219 61.07
Age Group
15-44 246 (5.48%) 106 43.09
45-54 490 (10.92%) 224 45.71
55-64 949 (21.14%) 497 52.37
65-74 1534 (34.17%) 998 65.06
75+ 1270 (28.29%) 1068 84.09
Typology
Rural 448 (9.98%) 317 70.76
Averagely Urban 698 (15.55%) 457 65.47
Urban 3247 (72.33%) 2104 64.80
Unknown 96 (2.14%) 15 15.63
Topography
Colon 2872 (63.98%) 1826 63.58
Rectum 1617 (36.02%) 1067 65.99
Total 4489 (100%) 2893 64.45
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The results in Table 5.1 seem to show different scenarios regarding gender. There
was a bigger incidence of this cancer in men than in women and prognosis also seems
to be worse for men, since the percentage dying during follow-up was bigger. The most
affected ages were over 65 years old representing about 63% of the total cohort. Deaths
during treatment were also higher between the older patients, specially the ones above 75
years old.
5.2 Survival Estimates
This section aims to present an overview of the survival for the set of patients. The survival
rates were estimated for each variable in order to compare the influence of the diferent
groups in the survival. The relative survival method for cancer survival estimation was
Ederer II.
5.2.1 Sex
Figure 5.1: Relative Survival by Sex
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Table 5.2: Survival by Sex
Years after Diagnosis
1 5 10 Log-Rank Test
Observed Survival
Male 64.6% 44.2% 34.1% p-value=0.001
Female 65.7% 46.3% 39.9%
Relative Survival
Male 69.5% 55.5% 51.2%
Female 69.4% 54.5% 53.5%
Observed survival rates seem to indicate a difference in prognosis among genders, with
better survival rates for women during the 10 years after diagnosis. When looking to
relative survival, the difference is not that clear. Figure 5.1 suggests similar survival for
men and women until the first two and a half years, then men seem to resist better to
the disease but only until seven years after diagnosis, after that female rates show better
results for long term survival.
5.2.2 Age Group
Figure 5.2: Relative Survival by Age Group
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Table 5.3: Survival by Age Group
Years after Diagnosis
1 5 10 Log-Rank Test
Observed Survival
15-44 73.7% 60.1% 56.8% p-value<0.001
45-54 77.9% 58.7% 54.3%
55-64 74.1% 56.2% 48.2%
65-74 67.1% 47.5% 37.9%
75+ 49.1% 25.6% 15.7%
Relative Survival
15-44 74.0% 60.9% 58.2%
45-54 78.6% 60.5% 57.5%
55-64 75.6% 60.4% 55.1%
65-74 70.7% 57.0% 54.1%
75+ 58.3% 45.2% 47.2%
Analyzing the survival by age group from Figure 5.2 and Table 5.3 stands out that patients
diagnosed with more than 75 years old had the worst chances of beating the disease, fol-
lowed by the age group bellow with ages between 65 and 75. Persons diagnosed younger
than 65 years old reaveled better survival estimates, with long term survival results de-
creasing as we go along age groups.
5.2.3 Typology
Figure 5.3: Relative Survival by Typology
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Table 5.4: Survival by Typology
Years after Diagnosis
1 5 10 Log-Rank Test
Observed Survival
Rural 58.1% 38.6% 31.5% p-value=0.0213
Averagely Urban 64.8% 46.9% 37.6%
Urban 66.1% 45.8% 37.3%
Relative Survival
Rural 62.8% 48.6% 47.8%
Averagely Urban 69.0% 56.6% 52.4%
Urban 70.4% 55.7% 53.0%
Relative survival curves in Figure 5.3 and estimates in Table 5.4 suggest that patients who
live in rural places showed inferior survival rates during the all follow-up period compared
with persons who reside in more urbanized regions.
5.2.4 Topography
Figure 5.4: Relative Survival by Topography
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Table 5.5: Survival by Topography
Years after Diagnosis
1 5 10 Log-Rank Test
Observed Survival
Colon 65.3% 46.0% 37.7% p-value=0.1612
Rectum 64.8% 43.6% 35.0%
Relative Survival
Colon 69.8% 56.7% 54.6%
Rectum 68.8% 52.2% 48.2%
In the first two years after diagnosis survival estimates from Table 5.5 were identical for
both types of cancer , being near 70% in the first year. However, after the second year the
percentage of cancer in the rectum patients who deceased exceeded the ones with cancer
in the colon.
5.3 Cox regression model for survival
Similar to what was presented in previous chapter, in this section a Cox regression model
is fitted for the population in study. Backward selection method was also applied and no
significant interations between variables were identified.
Table 5.6: Cox model fitted to available data from Colorectal cancer patients
Years after Diagnosis
Prognostic Factor Category Hazard Ratio 95% CI p-value
Sex Male 1
Female 0.84 ]0.78,0.91[ <0.001
Age Group <55 1
55-64 1.22 ]1.05,1.39[ 0.008
65-74 1.69 ]1.49,1.91[ <0.001
75+ 3.21 ]2.84,3.64[ <0.001
Topography Colon 1
Rectum 1.10 ]1.02,1.19[ 0.012
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Figure 5.5: Cox-Snell Residual
Figure 5.5 shows that hazard function follows the 45 degree line very closely except
for very large values of time, therefore the final model fits data well.
Interpreting hazard ratios from the final model results in table 5.6, we see that in
women the rate of relapse is 16% lower than in man (considering all other variables con-
stant). Age groups bellow 55 years old did not revealed significant statistic differences
between them, but when comparing to older ages there were actually differences in sur-
vival. Assuming age lower than 55 as a reference group, we see that when comparing to
a patient in 55-64 age group, the risk of death increases by 21%. If we go to an age be-
tween 65 and 74 the risk is 69% higher. And when comparing the reference group to ones
with 75 or more years old, the risk has a remarkable rise by 221%. Analyzing predictor
topography, if we go to a patient with cancer in the colon to one with cancer developed in
the rectum there is indication of 10% more risk of dying.
5.4 Estimating and Modeling cure with Cure Models
A Flexible parametric cure model was applied to all variables in the data, as well as
interactions between them. Backward variables elimination by likelihood-ratio tests was
also used to get the final model. The number and place of knots sensitivity was evaluated
and once again the results confirmed that the model was invariant to that. So, the final
model uses the default knots positions. Figures 5.6, 5.7 and 5.8 show the estimated relative
survival from Ederer II plotted against predicted survival from the model to visually assess
its fit. Figure 5.7 shows that observed data of patients above 75 years old it is not properly
fitted by the model, because life table estimates tend to increase in the last years of follow
up. And despite its confidence intervals get bigger reflecting uncertainty and possibility
of leveling of, patients in these ages will be excluded from the model. For all the age
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groups under 75 the assumption of cure is verified with estimates of relative survival
tended to level off within 10 years of follow-up. The final parametric cure model include
all variables in the study with exception of typology.
Figure 5.6: Predicted Survival from the Flexible parametric cure model, compared to life
table estimates of relative survival for both genders
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Figure 5.7: Predicted Survival from the Flexible parametric cure model, compared to life
table estimates of relative survival for age groups
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Figure 5.8: Predicted Survival from the Flexible parametric cure model, compared to life
table estimates of relative survival for typology
Table 5.7: Estimated proportion cured (%) and 95% confidence intervals by sex and age
group
Cancer of the colon
Age <45 Age 45-54 Age 55-64 Age 65-74 All <75
Men 55.13 ]42.45 , 66.11[ 58.43 ]49.39 , 66.42[ 54.93 ]48.40 , 60.98[ 53.86 ]47.67 , 59.64[ 54.44 ]50.72 , 58.00[
Women 66.84 ]55.21 , 76.08[ 61.75 ]52.70 , 69.58[ 58.78 ]51.66 , 65.21[ 58.62 ]52.53 , 64.21[ 59.68 ]55.90 , 63.25[
All 61.47 ]52.91 , 68.93[ 60.01 ]53.72 , 65.72[ 56.70 ]51.88 , 61.22[ 56.24 ]51.93 , 60.32[
Table 5.8: Estimated proportion cured (%) and 95% confidence intervals by sex and age
group
Cancer of the rectum
Age <45 Age 45-54 Age 55-64 Age 65-74 All <75
Men 55.80 ]39.67 , 69.20[ 52.93 ]42.75 , 62.10[ 52.99 ]44.75 , 60.56[ 47.17 ]39.72 , 54.25[ 50.78 ]46.17 , 55.20[
Women 57.66 ]41.84 , 70.61[ 58.24 ]45.65 , 68.89[ 54.87 ]45.16 , 63.55[ 49.00 ]40.68 , 56.80[ 52.66 ]47.47 , 57.58[
All 56.08 ]44.93 , 65.82[ 54.24 ]46.46 , 61.37[ 53.43 ]47.19 , 59.26[ 48.16 ]42.62 , 53.47[
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Figure 5.9: Predicted Survival of Uncured for Men
Figure 5.10: Predicted Survival of Uncured for Women
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Tables 5.7 and 5.8 summarize the estimated cure percentages results of the final
model by topography. As expected, independent on the carcinogen location, the chance
of cure decreased with advanced age at diagnosis for both genders. Looking at the results
by gender there is evidence in all ages that men are bellow the chances of women beating
the cancer. Besides that, the part of the large intestine where cancer develops, whether
colon or rectum also seems to influence the cure proportion. Patients in the study with
cancer of the rectum revealed lower chances of achieving cure when compared with ones
with cancer developed in the colon.
A more detailed analysis on the results of cancer of the colon indicates a percentage
of cure above 50% for all ages and genders. Younger female patients up to 45 years old
showed a cure percentage of 67%, while in men the cure was 55% with a confidence
interval containing percentage lower than 50%. Curiosly, men in the following age group
(45-54) revealed better odds with 58%, while women dropped to 62%. Nevertheless, the
deviation in the cure proportion compared to women became lower. The two older age
groups in the model have similar results for cure proportion, men’s ranging from 55% to
54% and women’s estimate of about 58%.
5.5 Discussion
In this study, methods of relative survival were attempted to be applied and analyzed to
the available data set. Like in the Melanoma case study, specific cause of death was not
available for all patients in the data and it was preferable to use relative survival approach
instead of cause-specific survival analysis. In section 5.2, survival estimates suggest sim-
ilar prognosis for both men and women. With a 5-year relative survival rate of 56% and
55%, respectively. Survival curve seems to reach a plateu indicating that patients expe-
rience long-term survival. However, when fitting a Cox regression model, statistically
significant differences in prognosis between genders were observed. Men, actually, have
higher risk of death. Patient age at diagnosed seem to have influence in prognosis, dur-
ing the follow-up period relative survival estimates are lower as we go from the newest
to the oldest age group. Looking at relative survival estimates there also seem to be a
distinct correlation between survival and region type in which patients live, with worse
prognosis scenarios for ones who came from rural areas. Nevertheless, cox regression
model proved no statistical evidence of differences. topography of the cancer, whether it
developed in the rectum or in the colon, led to discrepancies in patient’s prognosis with
statistical significance tested in Cox regression model. Rectum cancer has poorer survival
rates and increases in approximately 10% the mortality rate. Colon and rectal cancer
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are often referred as colorectal cancer since they share many features. Notwithstanding,
many studies have reported differences in survival and cure with advantages in survival
for colon cancer patients [36]. Our findings are consistent with previous literature and
moreover, is relevant to notice that relative survival estimates, Cox regression model and
cure model approach are in accordance and can be seen as complementary methods. Rel-
ative survival estimates provide an overview to the survival over time since diagnosis,
hazard ratios from Cox model evaluate which features are more associated with success
results on survival and cure model indicates the cure percentages and the prognosis for
those who are not able to achieve cure. Figure 5.9 and 5.10 shows that patients who are
not likely to achieve cure have survival tending to zero, as expected since they actually
die. Their survival dramatically decreases within the first 5 years of follow-up to approx-
imately 0% for all ages, genders and even tumour topography. It would be interesting if
the available data could provide records over a longer period of time, with registrations
before 1998. In that case we would be able to study temporal trends in survival, cure and
also perceive the underlying reasons for those trends. Thus, future population-based data
studies to be performed will play an important role in determining whether or not there
is a meaningful progress in patient survival and cure achievement. Possibility of cure for
colorectal cancer is reasonable and we may roughly say it is above 50%.
Chapter 6
Conclusion
In this thesis, methods for assessment and modelling of cancer survival were presented.
It was given special attention to a new class of survival regression models to estimate
cure fraction. The main aim was to apply this new models and demonstrate their value
to survival analysis as a complement to the standard techniques. Population-based data
from colorectal and melanoma skin cancer was provided from North Region of Portugal
Cancer Registry to perform the study. Relative survival rates and Cox regression model
provide an overview to the survival during the follow-up period and the potential prog-
nostic risk factors. However, information on cure percentages is only available when
applying cure models. Since this method is only reliable when cure is a reasonable as-
sumption, it enables to distinguish patients into ones who will achieve cure and ones who
do not. Thus, besides estimating cure proportion it also give information on the prognosis
for the uncured group. This is a great advantage of this approach, because it allows to
divided patients into two different groups with separete survival distributions for each.
Our findings can be useful in understanding cancer survival for colorectal and melanoma
skin cancer in the Northern Portugal. We found that, for both cancers in the study, men
have higher risk of dying during the follow-up compared to women. Survival rates and
cure percentages are actually lower for patients diagnosed with colorectal cancer in com-
parison with patients with melanoma skin cancer. We can roughly say that a patient
diagnosed with melanoma has a probability of beating the disease above 65%. However,
if diagnosed with colorectal cancer the probability decreases. Besides sex and age factors,
anatomical site of the cancer play an important role in the prognosis, with patients whose
cancer has developed in the rectum having worse survival.
Survival and cure patterns reflect the underlying response to cancer treatment and
suggest trends over time. Results can elucidate if the adopted health care techniques are
contributing to long-term survival or even better to reaching cure. Future researches in
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combination with these findings will potentially provide insights into how treatment and
prevention methods advances are changing survival and ultimately impacting cure.
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